Kaiser Peter
Chief Development Officer
Kaiser Peter has filed 6 SEC Form 4 filings (6 transaction rows) across 1 company, with disclosures dating back to 2025. 6 of those filings fall inside the rolling window. Most recent filing: Aug 26, 2026.
On the most recent filing, Kaiser Peter is listed as Chief Development Officer at OCULAR THERAPEUTIX, INC. Inside the rolling window, Kaiser Peter reported no open-market purchases and 5 open-market sales totaling $223K in OCUL. The largest disclosed transaction in the window is a sale of 9,653 OCUL shares on Oct 2, 2025, worth $106K.
Companies traded
Other insiders at OCUL
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$223K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Kaiser Peter made?
Kaiser Peter has filed 6 SEC Form 4 filings (6 transaction rows) across 1 company since 2025.
Which companies does Kaiser Peter trade?
Kaiser Peter has filed SEC Form 4 disclosures for 1 company, including OCUL.
When was Kaiser Peter's most recent SEC Form 4 filing?
Kaiser Peter's most recent SEC Form 4 filing on Tracefour is dated Aug 26, 2026.
What is Kaiser Peter's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Kaiser Peter is listed as Chief Development Officer.
What is Kaiser Peter's total buy and sell value in the current window?
Inside the rolling retention window, Kaiser Peter bought $0 and sold $223K based on SEC Form 4 filings.
What was Kaiser Peter's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 9,653 OCUL shares on 2025-10-02, worth $106K, per SEC Form 4 filings.